Antimicrobial resistance - Why do we have it and what can we do about it?

Expert Opinion on Investigational Drugs

Volumn 9, Issue 8, 2000, Pages 1707-1709

  Dougherty, T J ^a   Pucci, M J ^a   Bronson, J J ^a   Davison, D B ^a   Barrett, J F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; FOSFOMYCIN; NATURAL PRODUCT; QUINOLONE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; COST BENEFIT ANALYSIS; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EDITORIAL; GENE MUTATION; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; INFECTION RISK; MEDICAL RESEARCH; PRACTICE GUIDELINE; PUBLIC HEALTH; RISK ASSESSMENT;

EID: 0033869855     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.8.1707     Document Type: Editorial

References (0)